NEUROCRINE BIOSCIENCES INC(NBIX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
NEUROCRINE BIOSCIENCES INC (NBIX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NBIX at 76.5/100 on a 32-signal composite quality model, placing it at rank #82 of 2,960 stocks — the top 5% of the AI-ranked universe. NBIX scores in the top quartile across balance sheet strength (93.0), revenue growth (86.7), profitability (85.1). Shareholder dilution risk is elevated at 19.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NEUROCRINE BIOSCIENCES INC reports quarterly revenue of $959.0M, net income of $144.4M, free cash flow of $128.6M. Top institutional holders of NBIX by reported 13-F value include BlackRock, JPMORGAN CHASE, DODGE & COX, based on the most recent SEC filings. NBIX trades on the Nasdaq exchange and files with the SEC under CIK 914475. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEUROCRINE BIOSCIENCES INC directly from SEC EDGAR.
AI Quality Score
76.5/100
AI Rank
#82
Revenue
$959.0M
Net Income
$144.4M
Free Cash Flow
$128.6M
NBIX key financials by period
NEUROCRINE BIOSCIENCES INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.9B
$478.6M
21.6%
FY 2024
10-K
$2.4B
$341.3M
24.2%
FY 2023
10-K
$1.9B
$249.7M
13.3%
FY 2022
10-K
$1.5B
$154.5M
16.7%
FY 2021
10-K
$1.1B
$89.6M
9.0%
FY 2020
10-K
$1.0B
$407.3M
15.6%
Institutions holding NBIX
Institutional investors reporting a position in NEUROCRINE BIOSCIENCES INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue reached $959.0 million as CRENESSITY scaled to $183.5 million and newly acquired VYKAT XR added $54.3 million, but operating income rose only to $151.5 million on $2.83 billion Soleno deal costs.
Biggest Revenue Drivers
INGREZZA net product sales$716.5M
Volume growth in total prescriptions and record new prescriptions on strong patient demand
CRENESSITY net product sales$183.5M
Launched in the U.S. December 2024 as first-in-class FDA-approved treatment of classic CAH
Biggest Revenue Drivers
Total revenue: $959.0M
INGREZZA net product sales$716.5M
Volume growth in total prescriptions and record new prescriptions on strong patient demand
CRENESSITY net product sales$183.5M
Launched in the U.S. December 2024 as first-in-class FDA-approved treatment of classic CAH
VYKAT XR net product sales$54.3M
Inclusion of VYKAT XR sales following the acquisition of Soleno in May 2026
Other revenues$4.7M
Primarily royalties on AbbVie net sales of elagolix and Tanabe Pharma net sales of valbenazine
Largest Expense Items
Selling, general, and administrative$439.7M45.8% of total revenues vs 41.6%
Continued commercial investment plus $96.8M acquisition-related expenses, including $40.2M stock-based compensation on accelerated Soleno awards
Research and development$326.7M34.1% of total revenues vs 35.5%
Progression of Phase 3 programs for osavampator in MDD and direclidine in schizophrenia; higher headcount
Cost of revenues, excluding amortization of acquired intangible assets$23.2M2.4% of total revenues vs 1.6%
Higher net product sales, CRENESSITY royalties, $3.0M VYKAT XR inventory fair-value step-up amortization and $2.0M acquisition-related expenses
Amortization of acquired intangible assets$16.4M1.7% of total revenues vs 0.1%
Amortization of the $2.24 billion VYKAT XR developed product rights acquired with Soleno, over a 16-year useful life
Margins: Cost of revenues rose to 2.4% of revenues from 1.6%, and SG&A to 45.8% from 41.6% on Soleno deal costs; R&D eased to 34.1% from 35.5%.
Watch Items from the Filing
Customer concentration: Customers A, B and C were 34%, 26% and 28% of gross product sales; four customers exceed 90% of total gross product sales.
Liquidity fell to $481.7 million of cash and marketable securities from $2,543.4 million, after $2.36 billion net cash paid for Soleno.
August 2025 DOJ civil investigative demand on INGREZZA sales and marketing remains open; Zydus filed an ANDA with Paragraph IV certification against INGREZZA SPRINKLE.
Acquired VYKAT XR inventory step-ups of $41.5M (WIP) and $126.7M (finished goods) will burden cost of revenues over roughly four to six years.
Effective tax rate fell to 11.0% from 32.6%, aided by a discrete benefit from releasing part of a state deferred tax valuation allowance.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
